Omnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Omnicell, Inc. has received an average recommendation of "Hold" from eight ratings firms, with one sell rating, three hold ratings, and four buy ratings.
• The company's stock price target varies among firms, with an average target of $46.71, while Piper Sandler has reduced their target from $57.00 to $55.00.
• Omnicell reported earnings of $0.45 per share in its latest quarter, surpassing analysts' expectations of $0.30, and recorded a year-over-year revenue increase of 5% to $290.56 million.

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) have been assigned an average recommendation of "Hold" from the eight ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $46.7143.

Several research firms have recently commented on OMCL. Piper Sandler cut their price target on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Wells Fargo & Company lifted their target price on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Omnicell in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th.

Omnicell Stock Up 0.7%

OMCL stock opened at $31.10 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The company has a market cap of $1.43 billion, a price-to-earnings ratio of 62.20, a price-to-earnings-growth ratio of 6.57 and a beta of 0.88. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.74. The company has a fifty day moving average price of $31.43 and a 200 day moving average price of $30.21.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The firm had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. During the same quarter last year, the company posted $0.51 earnings per share. The business's revenue was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Sell-side analysts expect that Omnicell will post 1.09 earnings per share for the current year.

Insider Activity

In related news, EVP Corey J. Manley sold 3,880 shares of the company's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $33.25, for a total transaction of $129,010.00. Following the transaction, the executive vice president owned 110,653 shares of the company's stock, valued at $3,679,212.25. This represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 2.52% of the company's stock.

Institutional Investors Weigh In On Omnicell

Several institutional investors have recently made changes to their positions in OMCL. Raymond James Financial Inc. acquired a new stake in shares of Omnicell in the second quarter valued at about $26,000. Farther Finance Advisors LLC increased its holdings in Omnicell by 784.8% in the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company's stock valued at $36,000 after buying an additional 1,036 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock worth $50,000 after acquiring an additional 458 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Omnicell by 385.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company's stock worth $146,000 after acquiring an additional 3,932 shares during the period. Finally, AlphaQuest LLC grew its holdings in shares of Omnicell by 79.0% in the 1st quarter. AlphaQuest LLC now owns 6,400 shares of the company's stock worth $224,000 after acquiring an additional 2,824 shares during the period. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.